Thermo Fisher Scientific delivered a strong fourth quarter, with revenue increasing 5% YoY, driven by organic growth and strategic acquisitions. Despite a flat full-year revenue, the company achieved strong earnings performance, highlighting its industry leadership and innovation strategy. Key launches, such as the Thermo Scientific™ Iliad™ Transmission Electron Microscope and Stellar™ Mass Spectrometer, strengthened its market position.
📊 Income Statement Highlights (vs. Q4 FY23)
▫️Total Revenue: $11.40B vs. $10.89B (+5%)
- Organic Revenue Growth: +4%
- Core Organic Revenue Growth: +5%
▫️Net Income: $1.83B vs. $1.60B (+14%)
▫️GAAP Diluted EPS: $4.78 vs. $4.20 (+14%)
▫️Adjusted EPS: $6.10 vs. $5.67 (+8%)
▫️GAAP Operating Income: $2.02B vs. $1.85B (+9%)
▫️GAAP Operating Margin: 17.7% vs. 17.0%
▫️Adjusted Operating Income: $2.72B vs. $2.55B (+7%)
▫️Adjusted Operating Margin: 23.9% vs. 23.4%
▫️Free Cash Flow: $2.83B
💰 Revenue Breakdown by Segment (Q4 FY24)
▫️Life Sciences Solutions: $2.60B
▫️Analytical Instruments: $2.19B
▫️Specialty Diagnostics: $1.16B
▫️Laboratory Products & Biopharma Services: $5.94B
💼 Balance Sheet Highlights (vs. FY23)
▫️Total Assets: $97.32B
▫️Total Liabilities: $47.65B
▫️Equity: $49.55B
▫️Cash & Cash Equivalents: $4.01B
🔮 Future Outlook
Thermo Fisher enters 2025 in a strong position, leveraging its growth strategy and PPI Business System to drive innovation and market share. The company expects to continue expanding its biopharma services and proteomics research, aided by key acquisitions like Olink. The upcoming year will focus on streamlining drug development and launching advanced diagnostics and analytical instruments to support long-term growth.